Aptima shows higher specificity than Hybrid Capture 2 HPV test

Gen-Probe's Aptima HPV assay yielded strong results in the accurate detection of high-risk human papillomavirus infections that are associated with cervical cancer or precancerous lesions, according to data presented at the international conference of the European Research Organization on Genital Infection and Neoplasia, in Nice, France.

In the 1,528-patient FASE study, the assay had statistically identical sensitivity, but higher specificity, than the Hybrid Capture 2 test. Other studies of the Aptima HPV assay presented at EUROGIN showed similar results in geographically and clinically diverse patient groups, noted the US diagnostics firm.